How MaxCyte Has Evolved to Become Leading Technology Provider for Cell Engineering and Leveraged Its Flow Electroporation® Technology and Know-How to Launch Its Own Robust CAR Pipeline
MaxCyte, located in Gaithersburg, Maryland, is a unique biotech company that is a key anchor of the robust and growing Maryland cell and gene therapy industry. Founded in 1999, MaxCyte has been helping to unlock the full potential of cell and gene therapies by empowering the product development of its many blue chip life science partners and collaborators.
The company’s core technology is a proprietary, advanced cell engineering platform that is enabling leading companies like Kite Pharma, a Gilead Company, and CRISPR Therapeutics, among other major life science clients – ten of the top ten pharmaceutical companies to be exact – to advance their cell-based therapies for patients with high unmet medical needs. MaxCyte is a truly unique organization in that it is both a leading life sciences instrumentation company and is advancing its own portfolio of clinical-stage, cell-based therapies.
The organization has been in the cell therapy field since 2000 and was founded on proprietary technology that came from the Center for Blood Research in Boston and was spun out of Entremed, which is now known as CASI Pharmaceuticals. Among MaxCyte’s founders was the late Dr. John W. Holaday who served as the company’s first Chairman. Dr. Holaday was a tireless advocate and champion of MaxCyte’s mission.
Click here to read more via BioBuzz